Lower-Emission Inhalers May Offer Slight Clinical Benefits for COPD Patients

Inhalers are a crucial treatment for chronic obstructive pulmonary disease (COPD) and asthma, but a growing body of research highlights the significant environmental impact of certain types. New findings from UCLA Health suggest that switching to lower-emission inhalers may not only benefit the planet but could likewise lead to slightly improved clinical outcomes for COPD patients.

The Environmental Cost of Inhalers

A UCLA Health study published in JAMA in October 2025, found that inhalers generate over 2 million metric tons of carbon emissions annually in the United States—equivalent to the emissions of roughly 530,000 gas-powered cars each year. UCLA Health Study Finds Inhalers for Asthma and COPD Drive Significant Greenhouse Gas Emissions

The primary culprit behind these emissions is metered-dose inhalers (MDIs), which account for 98% of the total emissions over the past decade. MDIs utilize hydrofluoroalkane (HFA) propellants, potent greenhouse gases previously common in aerosol sprays.

New Research Highlights Potential Benefits of Lower-Emission Alternatives

Recent research from UCLA Health, published in JAMA Internal Medicine, investigated the clinical impact of different inhaler types. The study focused on patients with COPD and compared the effectiveness of various inhalers within the combined long-acting muscarinic antagonist (LAMA)-long-acting beta agonist (LABA) class. New study shows dry powder inhalers can improve patient outcomes and reduce environmental impact

Researchers discovered that inhalers with a lower carbon footprint were associated with slightly better clinical outcomes compared to MDIs. Specifically:

• The dry powder inhaler, umeclidinium-vilanterol, was linked to a 14% lower risk of moderate or severe COPD exacerbations compared to the MDI, glycopyrrolate-formoterol.
• The soft mist inhaler, tiotropium-olodaterol, showed a 6% lower risk of exacerbations compared to its metered-dose counterpart.

Importantly, the study found no significant differences in safety outcomes across all groups, including major cardiovascular events, urinary tract infections, and pneumonia.

Study Methodology

The research team analyzed insurance claims data from adults aged 40 and older newly prescribed one of three common COPD inhalers. Patients were continuously enrolled in a large commercial or Medicare Advantage health plan and were matched into comparison groups. Researchers tracked the time to first moderate or severe COPD flare-up, as well as hospitalizations for heart events, urinary tract infections, and pneumonia, over a period spanning 2016 to 2025.

Implications for Patients and the Environment

“The inhalers we studied are the first-line treatment for many patients with COPD, so it’s reassuring to see evidence that lower-emission inhalers may also be associated with slightly better clinical outcomes,” said Dr. William Feldman, a pulmonologist and health services researcher at UCLA Health and the study’s senior author.

While some patients may require MDIs, dry powder inhalers and soft mist inhalers represent a safe and effective option for most individuals with COPD, offering a potential win-win for both patient health and environmental sustainability.